Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 5, 2008, Pages 1140-1144

  Lewis, Russell E ^a,b   Albert, Nathan D ^b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aspergillus; Echinocandins; Pharmacodynamics

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FUNGAL VIRULENCE; IN VITRO STUDY; IN VIVO STUDY; LUNG ASPERGILLOSIS; MOUSE; NEUTROPENIA; NONHUMAN; RISK REDUCTION;

ANIMALS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; FEMALE; IMMUNOCOMPROMISED HOST; LIPOPROTEINS; MICE; MICE, INBRED BALB C; NEUTROPENIA;

EID: 42149128780     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn069     Document Type: Article

References (22)

1. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2W2: An update. Eur J Clin Microbiol Infect Dis 2002; 21: 161-72.
2. Upton A, Marr KA. Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr lnfect Dis Rep 2006; 8: 434-41.
3. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
4. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, non-comparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-97.
5. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
6. Kontoyiannis DP, Lewis RE. Combination chemotherapy for invasive fungal infections: What laboratory and clinical studies tell us so far. Drug Resist Updat 2003; 6: 257-69.
7. Wiederhold NP, Lewis RE. The echinocandin antifungals: An overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003; 12: 1313-33.
8. Petraitis V, Petraitiene R, Groll AH et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898-905.
9. Warn PA, Morrissey G, Morrissey J et al. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51: 913-9.
10. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A. NCCLS, Wayne, PA, USA, 2002.
11. Antachopoulos C, Meletiadis J, Sein T et al. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother 2007; 51: 881-7.
12. Lewis RE, Wiederhold NP. Murine model of invasive aspergillosis. Methods Mol Med 2005; 118: 129-42.
13. Wiederhold NP, Kontoyiannis DP, Chi J et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-71.
14. Bowman JC, Abruzzo GK, Anderson JW et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474-81.
15. Wiederhold NP, Tim VH, Chi J et al. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50: 469-73.
16. Abruzzo GK, Anderson CM, Douglas CM et al. The paradoxical in vitro response of Candida albicans to caspofungin. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract M-2155, p. 455. American Society for Microbiology, Washington, DC, USA.
17. Motulsky H, Christopoulos A. Fitting Models to Biological Data Using Linear and Nonlinear Regression. San Diego, CA: Graphpad Software, Inc., 2003.
18. Paderu P, Garcia-Effron G, Balashov S et al. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51: 2253-6.
19. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
20. Wiederhold NP, Wickes BL, Patterson TF. Increased gene expression of milogen-aclivated protein kinase A is associated with attenuated caspofungin (CAS) acfivity in Aspergillus fumigatus. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract M-364, p. 402. American Society for Microbiology, Washington, DC, USA.
21. Balloy V, Huerre M, Latge JP et al. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005, 73: 494-503.
22. Gumbo T, Drusano GL, Liu W et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with pesistent neutropenia. Antimicrob Agents Chemother 2007; 51: 968-74.